Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 New microtubular agents in pediatric oncology.

Literature DB >> 8880393

New microtubular agents in pediatric oncology.

Abstract

The taxanes are a new group of anticancer agents with a novel mechanism of action. They promote microtubule assembly and stabilize the microtubules. Paclitaxel (Taxol), the first agent in this group in clinical trials was isolated from the Pacific yew, Taxus brevifolia in 1971. Both in preclinical and clinical studies, paclitaxel and its semisynthetic analog docetaxel exhibit significant antitumor activity. This review will provide an overview of the clinical experience with the group of anti-microtubular agents, the taxanes in pediatric oncology.

Entities: Chemical Species

Mesh：

Substances：

Year: 1996 PMID： 8880393 DOI： 10.1007/bf00173682

Source DB: PubMed Journal: Invest New Drugs ISSN： 0167-6997 Impact factor: 3.850

33 in total

1. Relationships between the structure of taxol analogues and their antimitotic activity.

Authors: F Guéritte-Voegelein; D Guénard; F Lavelle; M T Le Goff; L Mangatal; P Potier
Journal: J Med Chem Date: 1991-03 Impact factor: 7.446

2. Phase I and pharmacodynamic study of taxol in refractory acute leukemias.

Authors: E K Rowinsky; P J Burke; J E Karp; R W Tucker; D S Ettinger; R C Donehower
Journal: Cancer Res Date: 1989-08-15 Impact factor: 12.701

3. A phosphoglycoprotein associated with taxol resistance in J774.2 cells.

Authors: S N Roy; S B Horwitz
Journal: Cancer Res Date: 1985-08 Impact factor: 12.701

4. Taxol assembles tubulin in the absence of exogenous guanosine 5'-triphosphate or microtubule-associated proteins.

Authors: P B Schiff; S B Horwitz
Journal: Biochemistry Date: 1981-05-26 Impact factor: 3.162

5. Direct photoaffinity labeling of tubulin with taxol.

Authors: S Rao; S B Horwitz; I Ringel
Journal: J Natl Cancer Inst Date: 1992-05-20 Impact factor: 13.506

6. Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer.

Authors: H Choy; W Akerley; H Safran; J Clark; V Rege; A Papa; M Glantz; Y Puthawala; C Soderberg; L Leone
Journal: J Clin Oncol Date: 1994-12 Impact factor: 44.544

7. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion.

Authors: E A Eisenhauer; W W ten Bokkel Huinink; K D Swenerton; L Gianni; J Myles; M E van der Burg; I Kerr; J B Vermorken; K Buser; N Colombo
Journal: J Clin Oncol Date: 1994-12 Impact factor: 44.544

1. Phase I study of paclitaxel with standard dose ifosfamide in children with refractory solid tumors: a Pediatric Oncology Group study (POG 9376).

Authors: James I Geller; Donna Wall; John Perentesis; Susan M Blaney; Mark Bernstein
Journal: Pediatr Blood Cancer Date: 2009-03 Impact factor: 3.167

1 in total